1. Home
  2. EPOW vs GLTO Comparison

EPOW vs GLTO Comparison

Compare EPOW & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$1.00

Market Cap

45.7M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$23.51

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPOW
GLTO
Founded
2014
2011
Country
China
Denmark
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.7M
54.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
EPOW
GLTO
Price
$1.00
$23.51
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
267.8K
106.8K
Earning Date
05-15-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$70,681,651.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
51.60
N/A
52 Week Low
$0.76
$2.01
52 Week High
$1.86
$38.33

Technical Indicators

Market Signals
Indicator
EPOW
GLTO
Relative Strength Index (RSI) 45.26 46.54
Support Level $0.94 $21.56
Resistance Level $1.10 $38.33
Average True Range (ATR) 0.08 4.26
MACD 0.01 -1.05
Stochastic Oscillator 59.06 9.01

Price Performance

Historical Comparison
EPOW
GLTO

About EPOW Sunrise New Energy Co. Ltd

Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: